At Day 28, an average of 10% placebo-adjusted treatment effect in FEV1 (L) was seen in patients regardless of baseline lung function

  • Among patients with FEV1 ≥25% to ≤50% there was an average treatment effect of 10.3% [6.3% CAYSTON (n=30), -4% placebo (n=30); p=0.0061].
  • Among patients with FEV1 >50% to ≤75% there was an average treatment effect of 10.1% [9.5% CAYSTON (n=50), -0.6% placebo (n=54); p<0.000].

Click here for study design for both subgroups

Disease severity chart

Two weeks after completion of drug treatment, the difference in FEV1 between CAYSTON and placebo groups continued but decreased to 6% (95% CI: 2%, 9%).